Neurocrine Biosciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Neurocrine Biosciences Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NBIX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000914475
- EIN
- 33-0525145
Board of directors
-
Christine A. Poon · DirectorSince 2023
-
Gary A. Lyons · DirectorSince 2023
-
George J. Morrow · DirectorSince 2023
-
Johanna Mercier · DirectorSince 2023
-
Kevin Charles Gorman · DirectorSince 2023
-
Kyle Gano · Director · Chief Executive OfficerSince 2024
-
Leslie Norwalk V · DirectorSince 2023
-
Richard F. Pops · DirectorSince 2023
-
Shalini Sharp · DirectorSince 2023
-
Stephen A. Sherwin · DirectorSince 2023
-
William H. Rastetter · DirectorSince 2023
Chief executives
Kyle Gano
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of May 21, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
85.1%
-
92.7%
-
92.7%
-
98.4%
Board connections
10 of this board's directors also sit on 19 other boards.
- via George J. Morrow
- via Richard F. Pops
- via Johanna Mercier
- via Leslie Norwalk V
- via Shalini Sharp
- via Stephen A. Sherwin
- via Leslie Norwalk V
- via William H. Rastetter
- via Gary A. Lyons
- via William H. Rastetter
- via Leslie Norwalk V
- via Shalini Sharp
- via Christine A. Poon
- via Christine A. Poon
- via Gary A. Lyons
- via Shalini Sharp
- via Christine A. Poon
- via Gary A. Lyons
- via Kevin Charles Gorman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $77,870,741
- 40 sales by 15 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 14, 2026 | Matt Abernethy Officer (Chief Financial Officer) | Open-market sale | −2,311 | $157.20 | $363,285 |
| Sep 14, 2026 | Boyer David W. Officer (Chief Corp. Affairs Officer) | Open-market sale | −826 | $157.45 | $130,051 |
| Sep 11, 2026 | Matt Abernethy Officer (Chief Financial Officer) | Grant or award | +5,020 | — | — |
| Sep 11, 2026 | Eric Benevich Officer (Chief Commercial Officer) | Grant or award | +6,275 | — | — |
| Sep 11, 2026 | Boyer David W. Officer (Chief Corp. Affairs Officer) | Grant or award | +3,587 | — | — |
| Sep 11, 2026 | Cooke Julie Officer (Chief Human Resources Officer) | Grant or award | +3,587 | — | — |
| Sep 11, 2026 | Delaet Ingrid Officer (Chief Regulatory Officer) | Grant or award | +4,483 | — | — |
| Sep 11, 2026 | Kevin Charles Gorman Director | Grant or award | +14,343 | — | — |
| Sep 11, 2026 | Kyle Gano Director, Officer (Chief Executive Officer) | Grant or award | +6,275 | — | — |
| Sep 11, 2026 | Keswani Sanjay Chandru Officer (Chief Medical Officer) | Grant or award | +3,914 | — | — |
| Sep 11, 2026 | Lippoldt Darin Officer (Chief Legal Officer) | Grant or award | +4,483 | — | — |
| Sep 11, 2026 | Jude Onyia Officer (Chief Scientific Officer) | Grant or award | +3,587 | — | — |
| Sep 11, 2026 | Matt Abernethy Officer (Chief Financial Officer) | Shares withheld for tax | −2,709 | $156.22 | $423,200 |
| Sep 11, 2026 | Eric Benevich Officer (Chief Commercial Officer) | Shares withheld for tax | −3,386 | $156.22 | $528,961 |
| Sep 11, 2026 | Boyer David W. Officer (Chief Corp. Affairs Officer) | Shares withheld for tax | −1,936 | $156.22 | $302,442 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.